Reuters logo
BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018
October 2, 2017 / 8:47 PM / 3 months ago

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

Oct 2 (Reuters) - Esperion Therapeutics Inc

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

* Esperion Therapeutics Inc - NDA submission for LDL-C lowering indication for bempedoic acid planned by Q1 2019

* Esperion - pivotal Phase 3 program for bempedoic acid/ezetimibe combination pill on track to initiate this quarter, top-line results expected by Q4 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below